ReviewFrontiers in molecular neuroscience2023
The role of microRNAs in pathophysiology and diagnostics of metabolic complications in obstructive sleep apnea patients.
Review in Frontiers in molecular neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Exposure to environmental toxicants and obstructive sleep apnea: a cross-sectional study.Future science OA · 2026Article
- Sex-Specific Association Between the Neutrophil-to-HDL Cholesterol Ratio and Hyperuricemia in Obstructive Sleep Apnea.Journal of clinical medicine · 2026Article
- Obstructive sleep apnea and seizures: pathophysiological mechanisms and clinical implications: a narrative review.Sleep & breathing = Schlaf & Atmung · 2026Review
- Molecular Biomarkers and Therapeutic Approach of Patients with Diabetes and Obstructive Sleep Apnea.International journal of molecular sciences · 2025Review
- The Effect of Sleep Disruption on Cardiometabolic Health.Life (Basel, Switzerland) · 2025Review
- Differential expression profiles and bioinformatics analysis of microRNAs in brown adipose tissue dysfunction induced by chronic intermittent hypoxia in obstructive sleep apnea.Frontiers in cell and developmental biology · 2025Article
- Integrative analysis of candidate MicroRNAs and gene targets for OSA management using in silico and in-vitro approach.Biotechnology notes (Amsterdam, Netherlands) · 2025Article
- Sleep and Sugar: Deciphering the 2003-2023 Research Landscape on Sleep Disorders and Diabetes Mellitus via Bibliometric Study.Journal of multidisciplinary healthcare · 2025Article
- Follistatin-like 1: a novel biomarker with a potential link to obstructive sleep apnea severity and treatment efficacy.Frontiers in endocrinology · 2025Article
- Review
- Shedding light on neurofilament involvement in cognitive decline in obstructive sleep apnea and its possible role as a biomarker.Frontiers in psychiatry · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obstructive sleep apnea (OSA) is one of the most common sleep disorders, which is characterized by recurrent apneas and/or hypopneas occurring during sleep due to upper airway obstruction. Among a variety of health consequences, OSA patients are particularly susceptible to developing metabolic complications, such as metabolic syndrome and diabetes mellitus type 2. MicroRNAs (miRNAs) as epigenetic modulators are promising particles in both understanding the pathophysiology of OSA and the prediction of OSA complications. This review describes the role of miRNAs in the development of OSA-associated metabolic complications. Moreover, it summarizes the usefulness of miRNAs as biomarkers in predicting the aforementioned OSA complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.